Please assess the completion status of the following clinical trial:

Trial Title: Human Factors Actual-Use Clinical Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 21 and \< 50 years.~2. Planned laparoscopic hysterectomy or myomectomy.~3. Tissue specimen is \<11 cm in maximum diameter based on standard preoperative assessment.~4. Pre-operative evaluation which may include imaging, cervical cancer screening, and endometrial biopsy has been completed.~5. Signed informed consent.~6. Willing to adhere to protocol requirements and complete follow-up.~Exclusion Criteria:~1. Subject is post-menopausal, defined as amenorrhea \>12 months in the absence of ovulation suppression.~2. Known or suspected malignancy of gynecological origin as determined by standard clinical practice.~3. Candidate for en bloc tissue removal, for example through the vagina or via a mini-laparotomy incision.~4. Hemoglobin \< 8 g/dl within 30 days prior to surgery.~5. Subject has a current history of undiagnosed genital bleeding.~6. Subject has an implanted electronic device where use of radiofrequency (RF) energy would be contraindicated (e.g., pacemaker, internal defibrillator).~7. Medical condition, surgical history, or intra-operative findings, which in the option of the investigator, precludes utilization of the Eximis CS System.~8. Known allergy to polyurethane, polyethylene, thermoplastic fluoropolymer and/or chlorinated polyvinyl chloride.~9. Concurrent participation in another therapeutic or interventional clinical trial with investigational pharmaceutical agent(s) or medical device(s) that could impact evaluation of this study as determined by the Investigator.~10. Inability to comply with the study procedures or follow-up in the opinion of the investigator.~11. Subject is pregnant.~12. Intraoperative Exclusion: Abdominal wall thickness at the umbilicus incision site is \> 8 cm.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Human Factors Actual Use (Type: EXPERIMENTAL): Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use

Based on this trial design, predict the completion outcome and termination type (if applicable).